Neuropsychiatric Effects in Patients With Invasive Prolactinomas Treated With Cabergoline

Background and objective Invasive prolactinoma accounts for 1-5% of all prolactinomas. Its mass and compromise of the diencephalon and frontal and temporal lobes may result in a range of neuropsychiatric symptoms that are often missed during initial evaluations. Cabergoline is a dopaminergic agonist...

Descripción completa

Detalles Bibliográficos
Autores principales: Calva-González, Metztli, Villanueva-Solórzano, Pedro Leonardo, Crail-Meléndez, Edgar D, Loya-Murguia, Kennya M, Dehesa Hernandez, Itzel Ariadna, Robles-Ramirez, Fernando, Rodríguez-Hernández, Luis A, Mondragón-Soto, Michel G, Flores-Vázquez, José Guillermo, Portocarrero-Ortiz, Lesly A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Endocrinology/Diabetes/Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315068/
https://www.ncbi.nlm.nih.gov/pubmed/37404423
http://dx.doi.org/10.7759/cureus.39869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315068/
https://www.ncbi.nlm.nih.gov/pubmed/37404423
http://dx.doi.org/10.7759/cureus.39869

Ejemplares similares